Pyxis Oncology Ownership
| PYXS Stock | USD 4.33 0.27 5.87% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 61.9 M | Current Value 62.6 M | Avarage Shares Outstanding 38 M | Quarterly Volatility 18.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pyxis Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in national income and product accounts. Pyxis Stock Ownership Analysis
About 23.0% of the company outstanding shares are owned by corporate insiders. The book value of Pyxis Oncology was at this time reported as 1.11. The company has Price/Earnings To Growth (PEG) ratio of 0.01. Pyxis Oncology recorded a loss per share of 1.41. The entity had not issued any dividends in recent years. Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people. To find out more about Pyxis Oncology contact MBA MD at 617 453 3596 or learn more at https://www.pyxisoncology.com.Besides selling stocks to institutional investors, Pyxis Oncology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pyxis Oncology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pyxis Oncology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pyxis Oncology Quarterly Liabilities And Stockholders Equity |
|
Pyxis Oncology Insider Trades History
About 23.0% of Pyxis Oncology are currently held by insiders. Unlike Pyxis Oncology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pyxis Oncology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pyxis Oncology's insider trades
Pyxis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pyxis Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pyxis Oncology backward and forwards among themselves. Pyxis Oncology's institutional investor refers to the entity that pools money to purchase Pyxis Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-06-30 | 396.1 K | Pier 88 Investment Partners Llc | 2025-06-30 | 367.2 K | Jane Street Group Llc | 2025-06-30 | 336.1 K | Decheng Capital Llc | 2025-06-30 | 326.8 K | Schulhoff & Co Inc | 2025-06-30 | 275 K | Goldman Sachs Group Inc | 2025-06-30 | 224.3 K | State Street Corp | 2025-06-30 | 186.1 K | Bank Of New York Mellon Corp | 2025-06-30 | 165 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 160.2 K | Pfizer Inc | 2025-06-30 | 7 M | Laurion Capital Management Lp | 2025-06-30 | 3.6 M |
Pyxis Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pyxis Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pyxis Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pyxis Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pyxis Oncology Outstanding Bonds
Pyxis Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pyxis Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pyxis bonds can be classified according to their maturity, which is the date when Pyxis Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| QORVO INC 3375 Corp BondUS74736KAJ07 | View | |
| QORVO INC 4375 Corp BondUS74736KAH41 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.